Targacept Backpedals on TC-6987 After Data Analysis Error

Targacept’s asthma candidate TC-6987 met only one of its co-primary endpoints in a Phase II study, the company revealed Tuesday, placing the asthma indication on shakier ground than previously reported. The company initially said TC-6987 met both its co-endpoints of change in forced expiratory volume (FEV1) compared with placebo when measured from baseline to pre-dosing on day 28 and when measured from baseline to two hours post-dosing on day 28.
Drug Industry Daily